Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisation

      Introduction and Aims: Treatment of Wilson Disease (WD) with chelating agents such as d-Penicillamine (DPA) or trientine decreases the pathologic accumulation of copper and removes circulating non-ceruloplasmin bound copper (NCC). There are no prior controlled studies comparing DPA with trientine. The study aim is to determine if maintenance therapy for WD with a novel tetrahydrochloride trientine formulation (TETA4) is safe and effective when compared to DPA.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect